| License: Creative Commons Attribution 4.0 PDF - Published Version (528kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-424998
- DOI to cite this document:
- 10.5283/epub.42499
Abstract
Cellular therapies, with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the ...
Owner only: item control page